Summary & Overview
HCPCS Q5140: Injection, adalimumab-fkjp, biosimilar, 1 mg
HCPCS Level II code Q5140 identifies an injectable biosimilar, adalimumab-fkjp, billed per 1 mg. As a biosimilar to adalimumab, this drug is used across multiple immune-mediated inflammatory conditions and is billed separately from the administration service. Nationally, biosimilar biologics like adalimumab-fkjp matter for cost management, formulary strategies, and clinical substitution policies given their potential to lower biologic therapy expenditure while maintaining therapeutic options.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the code’s clinical role and billing context, plus what to look for in payer coverage policies: how payers position biosimilars on formularies, typical site-of-service implications (outpatient clinic/physician office), and common considerations for billing the drug product separately from the injection or infusion service. The report also outlines where to find policy updates and benchmarks when available.
This summary is written for a national audience and focuses on the code’s clinical description, payer relevance, and the types of benchmarking and policy updates readers can expect to find in the full publication. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code Q5140 represents an injection of adalimumab-fkjp, a biosimilar formulation of adalimumab, dosed per 1 mg. This code describes the drug product itself for administration via injection.
Service Type: Injectable biologic drug administration
Typical Site of Service: Outpatient infusion/clinic, physician office, or other outpatient settings where biologic injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic inflammatory condition such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or hidradenitis suppurativa who requires subcutaneous biologic therapy. The clinician prescribes the biosimilar adalimumab-fkjp delivered as an injection dosed by milligram; clinic staff confirm prior authorization, verify immunization status and tuberculosis screening, review baseline labs (CBC, CMP, hepatitis B/C as indicated), and provide patient education on self-injection technique and adverse effects. The injection may be administered in an outpatient infusion or procedure clinic, rheumatology or dermatology office, or specialty pharmacy clinic; documentation includes medication name Q5140, dose in mg, lot number, route (subcutaneous), site, and patient tolerance. For initial dosing, patient observed for immediate reactions for 15–60 minutes per practice policy. Subsequent maintenance doses are administered per prescribed interval with monitoring for infection, injection site reaction, and therapeutic response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier used; standard service. | Use when no special circumstance modifier applies. |